Eluminex Biosciences focuses on the development of advanced engineered protein therapeutics, particularly in the fields of dermal facial aesthetics, regenerative medicine, and retinal disease. The company is notable for being the only entity capable of producing full-length triple helix recombinant human type III collagen, which is essential for skin quality and plays a significant role in maintaining a youthful appearance. This collagen is utilized in their aesthetic and regenerative medicine applications. Additionally, Eluminex has pioneered the creation of trispecific recombinant humanized fusion antibodies specifically designed for treating retinal diseases, showcasing their commitment to innovative therapeutic solutions.

In the ophthalmics sector, Eluminex is advancing a proprietary pipeline of tri-specific humanized antibodies aimed at addressing vision-threatening conditions. Their lead candidate, EB-105, is the first pentavalent trispecific antibody to enter clinical trials for diabetic macular edema, targeting multiple factors that contribute to retinal disease. The company is also developing EB-301 G2, a biosynthetic cornea device made from their recombinant collagen, aimed at treating corneal defects and preventing blindness. Through these initiatives, Eluminex is positioning itself as a leader in the biotechnology space, with a strong focus on enhancing patient outcomes in both aesthetic and ophthalmic applications.

China

Eluminex Biosciences is a clinical-stage biotechnology company focused on development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of ophthalmic diseases.

Eluminex Biosciences

Company Details